EBI-907

EBI-907 Suppliers list
Company Name: BOC Sciences  
Tel: 16314854226; +8616314854226
Email: inquiry@bocsci.com
Company Name: HANGZHOU CLAP TECHNOLOGY CO.,LTD  
Tel: 86-571-88216897,88216896 13588875226
Email: sales@hzclap.com
Company Name: Nanjing Shizhou Biology Technology Co.,Ltd  
Tel: 025-85560043 15850508050
Email: cindy.huang@synzest.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
EBI-907 Basic information
Product Name:EBI-907
Synonyms:EBI-907;1-Propanesulfonamide, N-[2-chloro-3-(1-cyclopropyl-8-methoxy-3H-pyrazolo[3,4-c]isoquinolin-7-yl)-4-fluorophenyl]-3-fluoro-
CAS:1581764-31-9
MF:C23H21ClF2N4O3S
MW:506.95
EINECS:
Product Categories:
Mol File:1581764-31-9.mol
EBI-907 Structure
EBI-907 Chemical Properties
Boiling point 685.6±65.0 °C(Predicted)
density 1.58±0.1 g/cm3(Predicted)
pka7.09±0.10(Predicted)
Safety Information
MSDS Information
EBI-907 Usage And Synthesis
DescriptionEBI-907 is a highly potent and orally efficacious B-RafV600E inhibitor. EBI-907 displays a low single-digit nanomolar activity (IC50 = 4.9 nM), which is >10-fold more potent than Vemurafenib (IC50 = 59 nM). EBI-907 also exhibits high potency in selectively inhibiting the proliferation of BRAF (V600E)-dependent cell lines (A375 and Colo205) and cellular Erk phosporylation, with superior activity to Vemurafenib. EBI-907, displaying potent activity against a number of important oncogenic kinases including BRK, FGFR1, c-Kit, and PDGFRb.
UsesEBI-907 is an orally active and highly potent B-RafV600E inhibitor. EBI-907 demonstrates excellent A375 and Colo-205 cellular antiproliferative activity with IC50 values of 13 nM and 14 nM, respectively. EBI-907 can also cause tumor regression in a B-RafV600E-dependent Colo-205 tumor xenograft model of mice. EBI-907 is promising for research of melanoma and B-RafV600E associated cancers[1][2].
References[1] Lu B, et al. Discovery of EBI-907: A highly potent and orally active B-Raf(V600E) inhibitor for the treatment of melanoma and associated cancers. Bioorg Med Chem Lett. 2016 Feb 1;26(3):819-823. DOI:10.1016/j.bmcl.2015.12.086
[2] Zhang J, et al. EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. Cancer Biol Ther. 2016;17(2):199-207. DOI:10.1080/15384047.2016.1139231
EBI-907 Preparation Products And Raw materials
Tag:EBI-907(1581764-31-9) Related Product Information
EBI-907 PLX4032 5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one RMC-7977 GDC-0879 CEP-32496 (free base)